Quantcast
Last updated on April 23, 2014 at 21:24 EDT

U.S. and European Rheumatologists Agree That a Therapy’s Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis

June 19, 2013

One of the Top Unmet Needs in RA is for Therapies with Greater Ability to Induce Remission Compared with Current Treatments, According to a New Report from Decision Resources

BURLINGTON, Mass., June 19, 2013 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis, the majority of surveyed U.S. and European rheumatologists cite a therapy’s induction of remission as one of the attributes that most influences their prescribing decisions. Over 60 percent and 70 percent of U.S. and European rheumatologists, respectively, rank the percentage of patients achieving remission at six months as one of the top three most persuasive end points when prescribing a new drug for rheumatoid arthritis.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase rheumatoid arthritis report entitled In a Market Filled with Efficacious Drugs, Which Efficacy and Safety Achievements Have the Greatest Influence with Physicians and Payers? finds that surveyed rheumatologists also indicate there is a moderate unmet need for therapies with a greater ability to induce remission. Therapies with a greater ability to induce remission at six months have a meaningful opportunity for differentiation.

The report also finds that, according to interviewed thought leaders and clinical data, tocilizumab (Roche/Chugai’s Actemra/RoActemra) has a minor advantage over AbbVie/Eisai’s Humira for its ability to effect remission at six months, whereas Pfizer/Takeda’s Xeljanz is at a disadvantage to Humira on this end point.

“However, in spite of thought-leader opinion and clinical trial data support for IV tocilizumab’s excellent efficacy, the drug is predominantly used as a later-line biologic because of payer restrictions, concerns about monitoring and managing its side effects, its more-limited postmarketing experience and its need for IV infusion,” said Decision Resources Senior Director Madhuri Borde, Ph.D.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

SOURCE Decision Resources


Source: PR Newswire